Vodafone and AstraZeneca announce partnership for mHealth patient services

Newbury and London, UK, March 18, 2014 – Vodafone and AstraZeneca have announced a global partnership to use mobile health (mHealth) services to improve health outcomes for patients with cardiovascular conditions. The collaboration will create new mobile and internet-based services to support patients through their treatment journey, improving medication adherence and giving patients confidence to manage their condition more effectively.

Vodafone will provide the technology, infrastructure and expertise for these services, as well as the ability to capture data from a variety of sources to improve overall engagement between patients and their Health Care Professionals (HCPs).

HCPs will be able to give patients the option to use these mHealth services, as an integral part of the patient care process, empowering them to manage their conditions as part of their daily routine. Patients will have access to educational material – personalised for their needs – and will benefit from coaching and treatment support to help manage their medication and lifestyle changes, and track their treatment progress.

The project will be led by the Intelligent Pharmaceutical Group within AstraZeneca, part of Global Medicines Development, working in close collaboration with the in-country marketing teams. Services will be designed to work across geographies, with the ability to adapt to local variations in regulations and patient care. Astra Zeneca has selected Vodafone in light of Vodafone’s experience in delivering – and ability to scale – mHealth services.

 

Vodafone Director for Machine-to-Machine, Erik Brenneis (pictured), said: “Bringing together the best in connectivity with the best in treatment and education will create powerful and compelling outcomes for patients. AstraZeneca is a global leader in the mHealth field and we are delighted to work with them to develop these innovative services”.

 

Andy Jones, Vice President Pharmaceutical Innovation at AstraZeneca, commented,: “It is really exciting to see the progress being made in this area. This work is an excellent example of collaboration between AstraZeneca and Vodafone. Together we believe we are delivering something that will bring real benefit to patients in this important therapeutic area”.

 

a.weber@wkm-global.com

Recent Posts

The transformation of IoT: The role of hyperscalers in the rise of IoT

The number of connected IoT devices is expected to reach 17 billion by 2030 -…

2 years ago

Aeris to acquire IoT business from Ericsson

Ericsson and Aeris Communications, a provider of Internet of Things (IoT) solutions based in San…

2 years ago

Telenor IoT passes milestone of 20mn SIM cards

Telenor, the global IoT provider and telecom operator, has experienced rapid growth over the last…

2 years ago

Globalstar, Wiagro to supply IoT transmitters for agtech applications

Globalstar, Inc. has announced a commercial agreement with Wiagro, an Agtech start-up from Argentina. Globalstar is supplying Wiagro with…

2 years ago